Radiopharm Theranostics Limited Stock Analysis & AI Score
Radiopharm Theranostics Limited (RADX) has an ST Score of 43.1 (C), driven by its Growth (A) and held back by its Profitability (F). Analysts rate it Buy with a $6.00 price target (+281.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Radiopharm Theranostics Limited (RADX) has an ST Score of 43.1 (C), driven by its Growth (A) and held back by its Profitability (F). Analysts rate it Buy with a $6.00 price target (+281.7% upside).
- Strongest
- GrowthA
- Weakest
- ProfitabilityF
All factor grades
- GrowthA
- ForecastA
- ValuationC
- Financial StrengthC
- MomentumD-
- ProfitabilityF
Contact
RADX stock: frequently asked questions
What is RADX's ST Score?
Radiopharm Theranostics Limited (RADX) has an ST Score of 43.1 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RADX a buy, hold, or sell?
Analysts rate RADX a Buy, with a price target of $6.00 (+281.7% vs the current price). Our ST Score grades it C (43.1/100). The ST Score is a data-driven signal, not a recommendation.
What are RADX's factor grades?
Valuation C, Profitability F, Financial Strength C, Momentum D-, Growth A, Forecast A.
What is RADX's valuation grade?
Radiopharm Theranostics Limited (RADX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RADX's growth grade?
Radiopharm Theranostics Limited (RADX) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RADX's profitability grade?
Radiopharm Theranostics Limited (RADX) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RADX's financial strength grade?
Radiopharm Theranostics Limited (RADX) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RADX?
The average analyst price target for Radiopharm Theranostics Limited (RADX) is $6.00 from 1 analysts, which is +281.7% versus the recent price of $1.57.